Boston Scientific Corporation $BSX Stock Holdings Increased by GDS Wealth Management

GDS Wealth Management grew its position in shares of Boston Scientific Corporation (NYSE:BSX) by 8.4% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 122,077 shares of the medical equipment provider’s stock after buying an additional 9,428 shares during the period. GDS Wealth Management’s holdings in Boston Scientific were worth $11,918,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Vanguard Group Inc. boosted its holdings in shares of Boston Scientific by 1.9% in the 2nd quarter. Vanguard Group Inc. now owns 137,134,110 shares of the medical equipment provider’s stock valued at $14,729,575,000 after buying an additional 2,545,381 shares during the period. State Street Corp lifted its holdings in Boston Scientific by 1.1% in the second quarter. State Street Corp now owns 65,191,864 shares of the medical equipment provider’s stock worth $7,002,258,000 after acquiring an additional 713,379 shares during the last quarter. Geode Capital Management LLC boosted its stake in Boston Scientific by 2.0% in the second quarter. Geode Capital Management LLC now owns 32,424,982 shares of the medical equipment provider’s stock valued at $3,466,320,000 after acquiring an additional 622,602 shares during the period. Norges Bank bought a new position in shares of Boston Scientific during the second quarter valued at approximately $2,089,937,000. Finally, Invesco Ltd. raised its position in shares of Boston Scientific by 1.4% during the 2nd quarter. Invesco Ltd. now owns 16,851,518 shares of the medical equipment provider’s stock worth $1,810,022,000 after purchasing an additional 226,578 shares during the period. 89.07% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the company. Erste Group Bank lowered Boston Scientific from a “buy” rating to a “hold” rating in a research report on Friday, October 3rd. Robert W. Baird boosted their price target on shares of Boston Scientific from $123.00 to $128.00 and gave the company an “outperform” rating in a report on Wednesday, October 1st. Leerink Partners increased their price objective on shares of Boston Scientific from $127.00 to $128.00 and gave the stock an “outperform” rating in a report on Wednesday, October 1st. Royal Bank Of Canada lifted their price objective on shares of Boston Scientific from $125.00 to $130.00 and gave the company an “outperform” rating in a research report on Wednesday, December 17th. Finally, The Goldman Sachs Group restated a “buy” rating and issued a $112.00 target price on shares of Boston Scientific in a research report on Friday, January 9th. One analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $123.89.

Insider Buying and Selling at Boston Scientific

In related news, EVP Arthur C. Butcher sold 17,313 shares of Boston Scientific stock in a transaction dated Monday, December 1st. The stock was sold at an average price of $101.55, for a total transaction of $1,758,135.15. Following the transaction, the executive vice president directly owned 23,600 shares of the company’s stock, valued at $2,396,580. The trade was a 42.32% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Ellen M. Zane sold 12,891 shares of the company’s stock in a transaction dated Thursday, November 6th. The shares were sold at an average price of $98.28, for a total transaction of $1,266,927.48. Following the completion of the sale, the director directly owned 24,134 shares of the company’s stock, valued at $2,371,889.52. The trade was a 34.82% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 93,095 shares of company stock valued at $9,305,450. 0.50% of the stock is owned by corporate insiders.

Boston Scientific Stock Up 1.4%

Boston Scientific stock opened at $92.56 on Friday. Boston Scientific Corporation has a 52 week low of $85.98 and a 52 week high of $109.50. The stock has a market cap of $137.22 billion, a price-to-earnings ratio of 49.50, a PEG ratio of 1.64 and a beta of 0.67. The company’s 50-day moving average price is $95.70 and its two-hundred day moving average price is $99.85. The company has a current ratio of 1.51, a quick ratio of 0.96 and a debt-to-equity ratio of 0.47.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share for the quarter, topping analysts’ consensus estimates of $0.71 by $0.04. Boston Scientific had a net margin of 14.43% and a return on equity of 19.46%. The company had revenue of $5.07 billion during the quarter, compared to analyst estimates of $4.97 billion. During the same period in the prior year, the business posted $0.63 EPS. The business’s revenue for the quarter was up 20.3% compared to the same quarter last year. On average, analysts expect that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.